RA01 is novel drug product and a first line therapy for preventing nosocomial infections at ICUs.

Our approach allows an immediate protection to patients admitted to ICU without generating AMR.




Technology advantages

  • Novel mechanism of action and target: temporary intracorporeal inhibition and specific removal of inhibitory anti-αGal antibodies.
  • Immediate protection to patients admitted to ICU.
  • High efficacy against high priority MDR Gram-negative bacteria (E. coli, P. aeruginosa, K. pneumoniae).
  • Lack of toxicity and side effects in rodents and primates (90 days follow up, in-house studies).
  • Dosage and route of administration already defined.
  • No generation of antimicrobial resistance. RA-01 is a drug of indirect activity against pathogens.
  • The synthetic process already defined: Low risk and costs for validating and scaling up the production.



Main advantages of RA01 versus other solutions


 PreventiveTherapeuticCostEfficacy at ICUMain drawbacks
Generic antibiotics

MediumAntimicrobial resistance (AMR)
Novel antibiotics

€€€€HighAntimicrobial resistance
Poor availability

€€€€LowRestricted to specific bacterial species
Extracorporeal removal of circulating antibodies

€€€€MediumTechnically sophisticated
Requires specialized personnel
Needs immunosuppression therapy

€€€Very lowNeeds 2 weeks to generate protection: too late for patients admitted to ICU
RA01 (RemAb)